603718.SH
*ST海利
SSE · Healthcare · Biotechnology · CN
CNY 2.93
−2.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 173.5M | 187.9M | 271.0M | 240.7M | 300.0M |
| Cost of Revenue | 54.2M | 52.3M | 107.9M | 117.0M | 123.1M |
| Gross Profit | 119.3M | 135.6M | 163.2M | 123.7M | 176.9M |
| Operating Expenses | |||||
| R&D Expense | 21.1M | 22.7M | 24.5M | 25.0M | 29.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 32.3M | 34.2M | 62.6M | 58.9M | 69.1M |
| Selling & Marketing Expense | 28.5M | 31.3M | 49.3M | 40.8M | 57.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 83.6M | 87.5M | 133.3M | 130.6M | 168.4M |
| Cost and Expenses | 137.7M | 139.7M | 241.2M | 247.7M | 291.5M |
| Operating Income (EBIT) | (595.2M) | (583.4M) | 174.5M | 55.2M | 69.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (196.7M) | (184.8M) | 208.1M | 56.0M | 131.2M |
| Income Tax Expense | 105.4M | 107.3M | 26.5M | 6.0M | 20.5M |
| Bottom Line | |||||
| Net Income | (316.0M) | (311.4M) | 171.2M | 62.9M | 121.6M |
| Earnings from Cont. Ops | (302.1M) | (292.2M) | 181.6M | 50.0M | 110.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (316.0M) | (311.4M) | 171.2M | 62.9M | 121.6M |
| Per Share | |||||
| Basic EPS | (CN¥0.49) | (CN¥0.48) | CN¥0.27 | CN¥0.10 | CN¥0.19 |
| Diluted EPS | (CN¥0.49) | (CN¥0.47) | CN¥0.26 | CN¥0.10 | CN¥0.19 |
| Revenue Per Share | CN¥0.27 | CN¥0.29 | CN¥0.43 | CN¥0.38 | CN¥0.47 |
| Shares | |||||
| Basic Shares Outstanding | 633.6M | 648.8M | 634.0M | 628.7M | 640.0M |
| Diluted Shares Outstanding | 633.6M | 648.8M | 634.0M | 628.7M | 640.0M |
| Profitability Metrics | |||||
| EBITDA | — | (568.2M) | 211.2M | 92.0M | 113.4M |
| D&A | — | 15.3M | 36.6M | 36.8M | 43.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026